Treatment interventions for Parkinson's disease: an evidence based assessment

[1]  Charles Howard Adler,et al.  Randomized, Placebo-Controlled Study of Tolcapone in Patients With Fluctuating Parkinson Disease Treated With Levodopa-Carbidopa , 1998 .

[2]  Double-blind comparison of standard Sinemet and Sinemet CR in patients with mild-to-moderate Parkinson's disease. , 1989, Neurology.

[3]  P. Krack,et al.  Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease. , 2001, The New England journal of medicine.

[4]  L. Ballering,et al.  Moclobemide and selegeline in the treatment of depression in Parkinson’s disease , 1997, Journal of neurology, neurosurgery, and psychiatry.

[5]  E. Tolosa,et al.  Early combination of bromocriptine and levodopa in Parkinson's disease: a prospective randomized study of two parallel groups over a total follow-up period of 44 months including an initial 8-month double-blind stage. , 1997, Clinical neuropharmacology.

[6]  D. Brooks,et al.  A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. , 2000, The New England journal of medicine.

[7]  R. Marconi,et al.  Pergolide monotherapy in the treatment of early PD , 1999, Neurology.

[8]  S. Factor,et al.  A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. , 2001, Archives of neurology.

[9]  O. Rascol,et al.  A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up. , 1994, Journal of neurology, neurosurgery, and psychiatry.

[10]  S Fahn,et al.  Falling asleep at the wheel: Motor vehicle mishaps in persons taking pramipexole and ropinirole , 1999, Neurology.

[11]  C. Goetz,et al.  Rating scales for dyskinesias in Parkinson's disease. , 1999, Movement disorders : official journal of the Movement Disorder Society.

[12]  J S Rakshi,et al.  Measuring the rate of progression and estimating the preclinical period of Parkinson’s disease with [18F]dopa PET , 1998, Journal of neurology, neurosurgery, and psychiatry.

[13]  C. Waters,et al.  Tolcapone in stable Parkinson's disease: Efficacy and safety of long-term treatment , 1997, Neurology.

[14]  U. Rinne.  Lisuride, a dopamine agonist in the treatment of early Parkinson's disease , 1989, Neurology.

[15]  O. Rascol,et al.  Sleep attacks and Parkinson's disease treatment , 2000, The Lancet.

[16]  O Rascol,et al.  Dopamine agonists. Their role in the management of Parkinson's disease. , 2001, Advances in neurology.

[17]  Richard S. J. Frackowiak,et al.  Transplantation of fetal dopamine neurons in Parkinson's disease: One‐year clinical and neurophysiological observations in two patients with putaminal implants , 1992, Annals of neurology.

[18]  John Seibyl,et al.  Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group. , 2000, JAMA.

[19]  M. Sandler,et al.  The pharmacology of selegiline. , 1992 .

[20]  J. Friedman,et al.  Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease , 1997, Neurology.

[21]  M. Pinter,et al.  Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson’s disease: a double blind, placebo controlled, randomised, multicentre study , 1999, Journal of neurology, neurosurgery, and psychiatry.

[22]  J. Hubble,et al.  The effect of deprenyl and levodopa on the progression of Parkinson's disease , 1995, Annals of neurology.

[23]  J Q Trojanowski,et al.  Transplantation of embryonic dopamine neurons for severe Parkinson's disease. , 2001, The New England journal of medicine.

[24]  D. Brooks,et al.  Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: A 6‐month interim report of a 3‐year study , 1998, Movement disorders : official journal of the Movement Disorder Society.

[25]  Dr Ira Shoulson.  Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa , 1996, Annals of neurology.

[26]  Anthony E. Lang,et al.  Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa , 1996 .

[27]  W. Poewe.  The Sydney multicentre study of Parkinson’s disease , 1999, Journal of neurology, neurosurgery, and psychiatry.

[28]  H. Allain,et al.  Efficacy and tolerability of tolcapone compared with bromocriptine in levodopa‐treated parkinsonian patients , 1999 .

[29]  K. Syndulko,et al.  Parkinson's disease: Cogentin with Sinemet, a better response. , 1982, Progress in neuro-psychopharmacology & biological psychiatry.

[30]  O. Lindvall,et al.  Pen injected apomorphine against off phenomena in late Parkinson's disease: a double blind, placebo controlled study. , 1995, Journal of neurology, neurosurgery, and psychiatry.

[31]  J. Jankovic,et al.  Parkinson's Disease and Movement Disorders , 1988 .

[32]  E. Tolosa,et al.  Immediate-release and controlled-release carbidopa/levodopa in PD , 1999, Neurology.

[33]  H. Lamb,et al.  Quetiapine : A review of its clinical potential in the management of psychotic symptoms in Parkinson's disease , 2000 .

[34]  A. Korczyn,et al.  A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson’s disease , 1999, Neurology.

[35]  M. Delong,et al.  Primate models of movement disorders of basal ganglia origin , 1990, Trends in Neurosciences.

[36]  K J Burchiel,et al.  Comparison of pallidal and subthalamic nucleus deep brain stimulation for advanced Parkinson's disease: results of a randomized, blinded pilot study. , 1999, Neurosurgery.

[37]  M. Murer,et al.  Levodopa in Parkinson’s Disease , 1999, Drug safety.

[38]  C. Adler,et al.  Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease , 1996, Neurology.

[39]  D. J. Kamphuis,et al.  Low‐dose bromocriptine therapy in Parkinson's disease , 1986, Neurology.

[40]  L. Parnetti,et al.  Alpha‐dihydroergocryptine in the treatment of de novo parkinsonian patients: results ofa multicentre, randomized, double‐blind, placebo‐controlled study , 2000, Acta neurologica Scandinavica.

[41]  D. Spencer,et al.  Unilateral transplantation of human fetal mesencephalic tissue into the caudate nucleus of patients with Parkinson's disease. , 1992, The New England journal of medicine.

[42]  Murat Emre,et al.  Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study , 2000, The Lancet.

[43]  Y. Mizuno,et al.  Potential of Neuroprotective Therapy in Parkinson’s Disease , 1994 .

[44]  J. Andersen,et al.  Anti‐depressive treatment in Parkinson's disease A CONTROLLED TRIAL OF THE EFFECT OF NORTRIPTYLINE IN PATIENTS WITH PARKINSON'S DISEASE TREATED WITH L‐DOPA , 1980, Acta neurologica Scandinavica.

[45]  A. Björklund.  Cell replacement strategies for neurodegenerative disorders. , 2000, Novartis Foundation symposium.

[46]  K. Marder,et al.  A population-based investigation of Parkinson's disease with and without dementia. Relationship to age and gender. , 1992, Archives of neurology.

[47]  Controlled‐release carbidopa/levodopa (CR4‐Sinemet) in Parkinson's disease patients with and without motor fluctuations , 1988, Neurology.

[48]  A. Sahs,et al.  Amantadine in Parkinson's disease , 1975, Neurology.

[49]  J. Ahlskog.  Drugs for the Treatment of Parkinson's Disease (Handbook of Experimental Pharmacology, Vol 88) , 1990 .

[50]  F. Savéry.  Amantadine and a fixed combination of levodopa and carbidopa in the treatment of Parkinson's disease. , 1977, Diseases of the nervous system.

[51]  O. Rascol,et al.  Levodopa monotherapy can induce “sleep attacks” in Parkinson's disease patients , 2001, Journal of Neurology.

[52]  L. Seeberger,et al.  A Home Diary to Assess Functional Status in Patients with Parkinson's Disease with Motor Fluctuations and Dyskinesia , 2000, Clinical neuropharmacology.

[53]  A J Lees,et al.  Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson’s disease , 1998, Journal of neurology, neurosurgery, and psychiatry.

[54]  H. Ruottinen,et al.  Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations. , 1996, Journal of neurology, neurosurgery, and psychiatry.

[55]  O. Rascol,et al.  Prevalence of orthostatic hypotension in Parkinson’s disease , 1997, Journal of neurology, neurosurgery, and psychiatry.

[56]  B. Snow,et al.  The Effect of Amantadine on Levodopa-induced Dyskinesias in Parkinson's Disease: A Double-blind, Placebo-controlled Study , 2000, Clinical neuropharmacology.

[57]  R. L. Rogers,et al.  Outcome Following Intrastriatal Fetal Mesencephalic Grafts for Parkinson's Patients Is Directly Related to the Volume of Grafted Tissue , 1997, Experimental Neurology.

[58]  K. Syndulko,et al.  Parkinson's disease: Cogentinr with sinemetr, a better response , 1982, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[59]  C. Adler,et al.  Tolcapone Improves Motor Function and Reduces Levodopa Requirement in Patients with Parkinson's Disease Experiencing Motor Fluctuations , 1997, Neurology.

[60]  M. Brin,et al.  Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. , 1993, The New England journal of medicine.

[61]  K. Kosaka,et al.  Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB) , 1996, Neurology.

[62]  Greenamyre Jt,et al.  N-methyl-D-aspartate antagonists in the treatment of Parkinson's disease. , 1991 .

[63]  C. Adler,et al.  Ropinirole for the treatment of early Parkinson's disease , 1997, Neurology.

[64]  M. Janssens,et al.  Multicentre European study of thalamic stimulation in parkinsonian and essential tremor , 1999, Journal of neurology, neurosurgery, and psychiatry.

[65]  W. Poewe,et al.  Beneficial effects of amantadine on L‐dopa‐induced dyskinesias in Parkinson's disease , 2000, Movement disorders : official journal of the Movement Disorder Society.

[66]  S. Konitsiotis,et al.  Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. , 1999, Archives of neurology.

[67]  C. O’Brien,et al.  N-methyl-D-aspartate antagonists in the treatment of Parkinson's disease. , 1991, Archives of neurology.

[68]  E. Tolosa,et al.  Immediate-release and controlled-release carbidopa/levodopa in PD A 5-year randomized multicenter study , 1999 .

[69]  M. Schiess,et al.  Immediate-release and controlled-release carbidopa/levodopa in PD: A 5-year randomized multicenter study. , 2000, Neurology.

[70]  P. Silcocks,et al.  The evidence based medicine workbook : critical appraisal for clinical problem solving , 1997 .

[71]  Mrc Psych,et al.  Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop , 1996 .

[72]  Edwards Rl,et al.  Pleuropulmonary fibrosis due to bromocriptine treatment for Parkinson's disease. , 1990 .

[73]  J. Jankovic,et al.  A multicenter double‐blind placebo‐controlled trial of pergolide as an adjunct to sinemet® in Parkinson's disease , 1994 .

[74]  O. Rascol,et al.  Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease. , 1996, Clinical neuropharmacology.

[75]  J. Schein,et al.  Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry. , 1998, The Journal of clinical psychiatry.

[76]  J. Jankovic,et al.  Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine. , 1993, The American journal of medicine.

[77]  R. Freeman,et al.  Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine Study Group. , 1997, JAMA.

[78]  O. Rascol,et al.  Ropinirole in the treatment of early Parkinson's disease: A 6‐month interim report of a 5‐year levodopa‐controlled study , 1998, Movement disorders : official journal of the Movement Disorder Society.

[79]  S. Fahn.  Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale , 1987 .

[80]  W. Oertel,et al.  Depression in Parkinson's disease. An update. , 2001, Advances in neurology.

[81]  L. Metman,et al.  Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease , 1998, Neurology.

[82]  H J Sagar,et al.  Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson's disease. A follow-up study of untreated patients. , 1992, Brain : a journal of neurology.

[83]  M. Guttman.  Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease , 1997, Neurology.

[84]  S. Fahn,et al.  A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease , 1998, Neurology.

[85]  A. Destée,et al.  Five-Year Follow-Up of Early Lisuride and Levodopa Combination Therapy versus Levodopa Monotherapy in de novo Parkinson’s Disease , 2000, European Neurology.

[86]  A. Lang,et al.  Surgery for Parkinson disease: A critical evaluation of the state of the art. , 2000, Archives of neurology.

[87]  N H Holford,et al.  Drug treatment effects on disease progression. , 2001, Annual review of pharmacology and toxicology.

[88]  C. Marsden,et al.  COMPARISONS OF THERAPEUTIC EFFECTS OF LEVODOPA, LEVODOPA AND SELEGILINE, AND BROMOCRIPTINE IN PATIENTS WITH EARLY, MILD PARKINSONS-DISEASE - 3-YEAR INTERIM-REPORT , 1993 .

[89]  O. Rascol,et al.  Continuous dopamine-receptor stimulation in early Parkinson's disease , 2000, Trends in Neurosciences.

[90]  S. Leucht.  Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. , 2001, Neurology.

[91]  B. Schmand,et al.  Unilateral pallidotomy in Parkinson's disease: a randomised, single-blind, multicentre trial , 1999, The Lancet.

[92]  K. Lübke.  A controlled study with Dihydergot on patients with orthostatic dysregulation. , 1976, Cardiology.

[93]  S. Stellar.  Outcome after stereotactic thalamotomy for parkinsonian, essential, and other types of tremor. , 1996, Neurosurgery.

[94]  S. Factor,et al.  Parkinson's disease: drug-induced psychiatric states. , 1995, Advances in neurology.

[95]  G. Ebersbach,et al.  Sudden daytime sleep onset in Parkinson's disease: Polysomnographic recordings , 2001, Movement disorders : official journal of the Movement Disorder Society.

[96]  J. Kesslak,et al.  Transplantation of embryonic dopamine neurons for severe Parkinson's disease , 2001 .

[97]  J. Larsen,et al.  Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations , 1998, Neurology.

[98]  G. Block,et al.  Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group. , 1997, European neurology.

[99]  A. Rajput,et al.  Tolcapone improves motor function in parkinsonian patients with the"wearing-off" phenomenon: A double-blind, placebo-controlled, multicenter trial , 1997, Neurology.

[100]  Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. Parkinson's Disease Research Group in the United Kingdom. , 1993, British medical journal.

[101]  P. Bossuyt,et al.  A comparison of continuous thalamic stimulation and thalamotomy for suppression of severe tremor. , 2000, The New England journal of medicine.

[102]  S Fahn,et al.  Committee. Unified Parkinson’s Disease Rating Scale. , 2001 .

[103]  H. Pakkenberg,et al.  Sustained‐release Madopar HBS® compared with standard Madopar® in the long‐term treatment of de novo parkinsonian patients , 1996, Acta neurologica Scandinavica.

[104]  Andrew J. Lees,et al.  Management of Parkinson's disease: An evidence‐based review , 2002, Movement disorders : official journal of the Movement Disorder Society.

[105]  R. Penn,et al.  Stereotactic pallidotomy for the treatment of Parkinson's disease , 1998, Neurology.

[106]  A. E. Lang,et al.  Anticholinergic Drugs and Amantadine in the Treatment of Parkinson’s Disease , 1989 .

[107]  A. Bonnet,et al.  [The Unified Parkinson's Disease Rating Scale]. , 2000, Revue neurologique.

[108]  Anthony E. Lang,et al.  Effect of deprenyl on the progression of disability in early Parkinson's disease. , 1989, The New England journal of medicine.

[109]  S. Suri,et al.  Pergolide-induced retroperitoneal fibrosis. , 2000, International journal of clinical practice.